CYTR Cytrx

CytRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. The company was founded on February 28, 1985 and is headquartered in Los Angeles, CA.
Company profile
Ticker
CYTR
Exchange
Website
CEO
Steven A. Kriegsman
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Bio-Techne • Enzon Pharmaceuticals • Denali Therapeutics • Allogene Therapeutics ...
SEC CIK
Corporate docs
IRS number
581642750
CYTR stock data
()
Investment data
Securities sold
Number of investors
Calendar
24 Mar 21
17 Apr 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Financial data from Cytrx earnings reports.
Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 10M | 10M | 10M | 10M | 10M | 10M |
Cash burn (monthly) | 866.17K | 510.59K | 474.26K | 569.1K | 866.17K | 511.68K |
Cash used (since last report) | 3.09M | 1.82M | 1.69M | 2.03M | 3.09M | 1.82M |
Cash remaining | 6.91M | 8.18M | 8.31M | 7.97M | 6.91M | 8.18M |
Runway (months of cash) | 8.0 | 16.0 | 17.5 | 14.0 | 8.0 | 16.0 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
14 Aug 20 | Earl W Brien | Common Stock, par value $0.001 per share | Option exercise | Aquire M | No | No | 0.26 | 150,000 | 39K | 590,247 |
14 Aug 20 | Earl W Brien | Stock Option CytRx Common Stock | Option exercise | Dispose M | No | No | 0.26 | 150,000 | 39K | 300,000 |
7 Aug 20 | Joel K Caldwell | Common Stock, par value $0.001 per share | Payment of exercise | Dispose F | No | No | 0.67 | 174,627 | 117K | 335,373 |
7 Aug 20 | Joel K Caldwell | Common Stock, par value $0.001 per share | Option exercise | Aquire M | No | No | 0.26 | 450,000 | 117K | 510,000 |
7 Aug 20 | Joel K Caldwell | Stock Option CytRx Common Stock | Option exercise | Dispose M | No | No | 0.26 | 450,000 | 117K | 0 |
7 Aug 20 | Louis Ignarro | Common Stock, par value $0.001 per share | Payment of exercise | Dispose F | No | No | 0.67 | 271,642 | 182K | 600,785 |
7 Aug 20 | Louis Ignarro | Common Stock, par value $0.001 per share | Option exercise | Aquire M | No | No | 0.26 | 700,000 | 182K | 872,427 |
7 Aug 20 | Louis Ignarro | Stock Option CytRx Common Stock | Option exercise | Dispose M | No | No | 0.26 | 700,000 | 182K | 0 |
7 Aug 20 | Steven A Kriegsman | Common Stock, par value $0.001 per share | Payment of exercise | Dispose F | No | No | 0.67 | 1,164,179 | 780K | 3,668,038 |
7 Aug 20 | Steven A Kriegsman | Common Stock, par value $0.001 per share | Option exercise | Aquire M | No | No | 0.26 | 3,000,000 | 780K | 4,832,217 |
Institutional ownership Q1 2021
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
13F holders |
Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares |
Current |
---|---|
Total value | 0 |
Total shares | 0 |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners |
Shares | Value |
---|
Financial report summary
?Content analysis
?
Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
antidilutive, approach, authoritative, Celgene, depositary, dividing, endanger, evidenced, German, IBM, jeopardize, lieu, lowest, MIPLYFFA, multiplied, NantKwest, neurodegenerative, possession, recalculated, regular, remotely, subdivision, subscribe, subscription, threshold, today, tradename, virtually
Removed:
accrual, acute, allocable, autoimmune, chronic, decreased, depressed, distinction, distinguishing, distributed, Document, Eric, float, fourteen, HTGC, inflammatory, initially, Instruction, investing, joining, Kratz, lender, Linkbase, literature, LLP, Master, opening, originally, planning, prepaid, production, ranged, ratably, remained, represented, representing, retrospective, Schema, Taxonomy, transition, unit, USA, viral, XBRL
Financial reports
10-K
2020 FY
Annual report
24 Mar 21
10-Q
2020 Q3
Quarterly report
13 Nov 20
10-Q
2020 Q2
Quarterly report
14 Aug 20
10-Q
2020 Q1
Quarterly report
14 May 20
10-K
2019 FY
Annual report
27 Mar 20
10-Q
2019 Q3
Quarterly report
14 Nov 19
10-Q
2019 Q2
Quarterly report
9 Aug 19
10-Q
2019 Q1
Quarterly report
15 May 19
10-K
2018 FY
Annual report
29 Mar 19
10-Q
2018 Q3
Quarterly report
2 Nov 18
Current reports
8-K
Departure of Directors or Certain Officers
8 Jan 21
8-K
Entry into a Material Definitive Agreement
17 Nov 20
8-K
CytRx Announces Voting Results from 2020 Annual Meeting and Issues New Investor Presentation
3 Sep 20
8-K
CytRx Announces Initiatives to Strengthen Corporate Governance and Support Strategic Priorities
24 Aug 20
8-K
Other Events
16 Jul 20
8-K
Other Events
29 Jun 20
8-K/A
Submission of Matters to a Vote of Security Holders
27 May 20
8-K
CytRx Corporation Provides Update on Management Change
11 Mar 20
8-K
Departure of Directors or Certain Officers
9 Jan 20
8-K
Entry into a Material Definitive Agreement
19 Dec 19
Registration and prospectus
S-8
Registration of securities for employees
23 Oct 20
25-NSE
Exchange delisting
24 Jun 19
424B5
Prospectus supplement for primary offering
11 May 18
424B3
Prospectus supplement
1 Apr 18
S-3
Shelf registration
20 Mar 18
424B5
Prospectus supplement for primary offering
30 Apr 17
424B2
Prospectus for primary offering
26 Apr 17
S-3
Shelf registration
6 Apr 17
424B3
Prospectus supplement
2 Apr 17
424B3
Prospectus supplement
2 Apr 17
Proxies
DFAN14A
Additional proxy materials by non-management
25 Aug 20
DFAN14A
Additional proxy materials by non-management
24 Aug 20
DEFA14A
Additional proxy soliciting materials
21 Aug 20
DFAN14A
Additional proxy materials by non-management
21 Aug 20
DFAN14A
Additional proxy materials by non-management
18 Aug 20
DFAN14A
Additional proxy materials by non-management
17 Aug 20
DFAN14A
Additional proxy materials by non-management
13 Aug 20
DEFA14A
Additional proxy soliciting materials
13 Aug 20
DEFA14A
Additional proxy soliciting materials
10 Aug 20
DEFC14A
Proxy in contested situation
9 Aug 20
Other
UPLOAD
Letter from SEC
11 Aug 20
UPLOAD
Letter from SEC
30 Jul 20
UPLOAD
Letter from SEC
21 Jul 20
UPLOAD
Letter from SEC
12 Jul 20
UPLOAD
Letter from SEC
12 Jul 20
EFFECT
Notice of effectiveness
1 Apr 18
CT ORDER
Confidential treatment order
14 Sep 17
EFFECT
Notice of effectiveness
20 Apr 17
CORRESP
Correspondence with SEC
18 Apr 17
UPLOAD
Letter from SEC
18 Apr 17
Ownership
4
CYTRX / Earl W Brien ownership change
20 Aug 20
4
CYTRX / STEVEN A KRIEGSMAN ownership change
13 Aug 20
4
CYTRX / LOUIS IGNARRO ownership change
13 Aug 20
4
CYTRX / Joel K Caldwell ownership change
13 Aug 20
SC 13G/A
Cytrx Corp
22 Jan 20
4
CYTRX / STEVEN A KRIEGSMAN ownership change
17 Dec 19
4
CYTRX / LOUIS IGNARRO ownership change
17 Dec 19
4
CYTRX / JOHN Y CALOZ ownership change
17 Dec 19
4
CYTRX / Joel K Caldwell ownership change
17 Dec 19
4
CYTRX / Earl W Brien ownership change
17 Dec 19
Patents
GRANT
Utility
Cytotoxic agents for the treatment of cancer
4 Jan 21
The present invention relates to a method of treating brain cancer comprising administering a therapeutically effective substance to a patient, wherein the therapeutically effective substance comprises: (I), or a pharmaceutically acceptable salt thereof, wherein X is a moiety that can be cleaved hydrolytically or enzymatically in the body of the patient in a pH-dependent manner.
APP
Utility
Cytotoxic Agents for the Treatment of Cancer
20 Nov 19
The present invention relates to a method of treating brain cancer comprising administering a therapeutically effective substance to a patient, wherein the therapeutically effective substance comprises: (I), or a pharmaceutically acceptable salt thereof, wherein X is a moiety that can be cleaved hydrolytically or enzymatically in the body of the patient in a pH-dependent manner.